


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
LLY
Eli Lilly and
$1014.49
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Investors confidence is positive

Trading below its fair value
Technical Indicators

5+ Days Down
LLY Price Performance
$924.37 (+9.75%)
$756.28 (+34.14%)
$789.8 (+28.45%)
$764.71 (+32.66%)
LLY has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk

LLY overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Reported a strong earnings

Above analyst estimates

Revenue increase YoY

Earnings increase YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity

Investors confidence is positive

Pays a reliable dividend
Future
Future

Earnings are forecast to grow

Trading below its fair value

Outperform the market
![]()
LLY Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential
LLY Street Sentiment is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels
Login to displayNVO
47.99
+0.88%
PFE
25.70
+0.35%
SNY
48.90
-1.59%
NVS
132.43
-0.96%
MRK
100.89
-1.37%
What is LLY current stock price?
What are LLY stock strengths?
What is LLY Risk Level?
What is LLY market cap and volume?
What is LLY current Stock IQ?
Should I buy LLY stock right now?
Is LLY a Strong Buy right now?
What does a 'Strong Buy' rating mean for LLY?
What does a 'Strong Sell' rating mean for LLY?
What factors influence LLY's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
LLY
Eli Lilly and
Current Price
$1014.49
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Investors confidence is positive

Trading below its fair value
Technical Indicators

5+ Days Down
Linked to LLY
NVO
47.99
+0.88%
PFE
25.70
+0.35%
SNY
48.90
-1.59%
NVS
132.43
-0.96%
MRK
100.89
-1.37%

LLY Price Performance
$924.37 (+9.75%)
$756.28 (+34.14%)
$789.8 (+28.45%)
$764.71 (+32.66%)
LLY Analysts Opinion
LLY Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Reported a strong earnings

Above analyst estimates

Revenue increase YoY

Earnings increase YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity

Investors confidence is positive

Pays a reliable dividend
Future
Future

Earnings are forecast to grow

Trading below its fair value

Outperform the market
![]()
LLY Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential
LLY Street Sentiment is extremely bullish and have positive views on the near-term outlook
LLY has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk

Average key support and resistance price levels
LLY Stock IQ
LLY Latest Analysis
Behind the Scenes of Eli Lillys Latest Options Trends. Whales with a lot of money to spend have taken a noticeably ish stance on Looking at options history for Eli Lilly (NYSE:) we detected 28 trades.If we consider the specifics of each trade it is accurate to state that 39% of the investors opened trades with ish expectations and 39% with bearish.From the overall spotted trades 14 are puts for a total amount of $2580123 and 14 calls for a total amount of $625243.Taking into account the Volume a
Thu Dec 4, 2025
Chinese Biotech Ming Yu Well Positioned For A Strong Hong Kong IPO.
Thu Dec 4, 2025
FDA Grants Full Approval To Eli Lillys Jaypirca For CLL/SLL . (RTTNews) - Eli Lilly and Co. (LLY) announced that the United States Food and Drug Administration (FDA) has approved Jaypirca (pirtobrutinib 100 mg and 50 mg tablets) for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic l
Thu Dec 4, 2025
FDA Expands Approval For Lillys Cancer Drug Jaypirca . (RTTNews) - Eli Lilly and Co. (LLY) announced that the FDA has expanded cancer med Jaypircas approval to include treatment for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent
Thu Dec 4, 2025
Eli Lilly And Indiana University Sign $40 Mln Agreement To Expand Clinical Trials In Indiana . (RTTNews) - Eli Lilly and Company (LLY) announced that it has entered into a new agreement with Indiana University (IU) to provide up to $40 million aimed at expanding access to clinical trials across Indiana. This initiative will give patients a critical pathway to Lillys lates
Thu Dec 4, 2025
Insiders Buy the Holdings of VHT ETF. A look at the weighted underlying holdings of the Vanguard Health Care ETF (VHT) shows an impressive 18.1% of holdings on a weighted basis have experienced insider buying within the past six months.Eli Lilly (Symbol: LLY) which makes up 13.99% of the Vanguard Health Care ETF
Wed Dec 3, 2025
1 Reason to Buy Eli Lilly Hand Over Fist Before the New Year. Key PointsEli Lilly has seen revenue soar thanks to its blockbuster weight loss drug portfolio.
Wed Dec 3, 2025
Bernstein Reaffirms Price Target on Eli Lilly (LLY) After Breakthrough Gains. Eli Lilly &. Company (NYSE:LLY) ranks among the Best Low Volatility Investments in December 2025. Eli Lilly &. Company (NYSE:LLY) reached another milestone on November 21 becoming the first drugmaker to join the exclusive $1 trillion club populated by tech behemoths and cementing its position as a weight-loss powerhouse. The companys stock has rallied more [….]
Wed Dec 3, 2025
Eli Lilly and Company (LLY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript.
Tue Dec 2, 2025
LLY Lowers Prices of Zepbound Vials for Cash Buyers on DTC Website. Eli Lilly trims Zepbound vial prices on LillyDirect offering lower monthly costs for self-paying patients across multiple doses.
Tue Dec 2, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.